Not quite ... screening does not equal enrolment. And the study started in July 2019 so a number of patients must have been screened before paxalisib was included in the study in 2021.
Unless I misunderstand the study design, which is possible, it has 3 investigational study arms and 1 control arm. The VAL-083 may end up with more patients as it also includes methylated patients.
For every 4 patients enrolled with either new, unmethylated GBM or recurrent GBM, I’d expect 1 patient in the paxalisib arm.
KZA Price at posting:
$1.22 Sentiment: Buy Disclosure: Held